. Background: Interest in a novel presentation of a known disease.
Study design: A case report of five clinical cases seen.
Methods: Case records were reviewed from horses that were diagnosed with AM after developing clinical signs following or during exercise.
Results: Five horses with increased serum muscle enzyme activities were identified. Clinical signs included exercise-induced rhabdomyolysis following light exercise (n = 3), perceived abdominal pain during light exercise (n = 1) and exercise intolerance (n = 1). AM was diagnosed by detecting hypoglycin A in serum (n = 3) or characteristic plasma acylcarnitine and urine organic acid profiles (n = 1). Muscle biopsy of one horse following abnormal exercise testing, revealed rhabdomyolysis and prominent lipid accumulation in oxidative fibres, consistent with AM. All cases resolved and returned to exercise following supportive management; one horse developed another episode of rhabdomyolysis. Sycamore exposure was confirmed in four cases.
Main limitations: Low case numbers.
Conclusions:
In these horses, myopathic signs were unusual, given the low levels of exercise prompting further investigation and, in each case, revealing underlying AM. Previous reports describe AM as a severe, commonly fatal disorder with systemic compromise; in contrast, these horses developed an exercise-associated myopathy following low-level athletic activity but had characteristic AM biochemical or histological features. Prognosis appears to be excellent for survival and horses can return to previous levels of exercise with supportive management. Subclinical hypoglycin A toxicity might predispose horses to exerciseinduced rhabdomyolysis following low levels of exercise and therefore should be considered when cases of exertional rhabdomyolysis cannot be explained. Objectives: To document muscle activity based on the GYS1 genetic status of Austrian cold blood horses.
Study design: Matched observational study.
Methods:
In clinically healthy Noriker horses matched for sex, body mass, and age either homozygous for GYS1 mutation (n = 7, affected), or homozygous without GYS1 mutation (n = 7, control) the muscle activity of the gluteus muscle was measured using surface EMG at walk and at trot. The density of the signal was calculated for each motion cycle as the number of its crossings with the baseline (BL) and with the 75, 50 and 25 percentile respectively, and compared with a t test for paired samples.
Results: There were significantly more crossings in control than in affected horses at baseline (walk 50 AE 20 vs. 37 AE 14; trot 56 AE 20 vs. 42 AE 18) and at all other percentiles evaluated.
Main limitations: Low sample size.
Conclusions:
Even before the development of signs of clinical disease, it was possible to show significant differences in sEMG signal density between affected and control horses. The difference in the number of active muscle units may represent the number of muscle fibres with the accumulation of clumped muscle glycogen present in the affected horses. The method of sEMG analysis used in the present study may potentially develop into a tool to identify type 2 PSSM, a similar disease currently without identified genetic basis. 
